The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell ...
Imugene has reported promising Phase 1b data for azer-cel, its allogeneic CD19 CAR T-cell therapy, in a CAR T-naïve cohort of patients with relapsed or refractory non-Hodgkin lymphoma and chronic ...
Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...
Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T-cell-targeted lipid nanoparticle carrying CD19 CAR mRNA (HN2301) generated ...
Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and BCMA ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Please provide your email address to receive an email when new articles are posted on . Most children with relapsed or refractory B-lineage acute lymphoblastic leukemia achieved complete remission ...
Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI. | Cancer immunotherapy company Liminatus Pharma has agreed to pay out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results